Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma.
Shirao K, Ohtsu A, Takada H, Mitachi Y, Hirakawa K, Horikoshi N, Okamura T, Hirata K, Saitoh S, Isomoto H, Satoh A. Shirao K, et al. Among authors: hirata k. Cancer. 2004 Jun 1;100(11):2355-61. doi: 10.1002/cncr.20277. Cancer. 2004. PMID: 15160338 Free article. Clinical Trial.
[Pharmacokinetics of S-1].
Hirata K, Horikoshi N, Tominaga K, Sohma K, Yamaguchi K, Okazaki M, Furuhata T, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Yamamitsu S, Shirasaka T. Hirata K, et al. Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:27-35. Gan To Kagaku Ryoho. 2006. PMID: 16897969 Review. Japanese.
A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32).
Kusano M, Aoyama T, Okabayashi K, Hirata K, Tsuji Y, Nakamori S, Asahara T, Ohashi Y, Yoshikawa T, Sakamoto J, Oba K, Saji S. Kusano M, et al. Among authors: hirata k. J Cancer Res Ther. 2018 Sep;14(Supplement):S761-S766. doi: 10.4103/0973-1482.179188. J Cancer Res Ther. 2018. PMID: 30249900 Free article. Clinical Trial.
Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
Sato Y, Takayama T, Sagawa T, Takahashi Y, Ohnuma H, Okubo S, Shintani N, Tanaka S, Kida M, Sato Y, Ohta H, Miyanishi K, Sato T, Takimoto R, Kobune M, Yamaguchi K, Hirata K, Niitsu Y, Kato J. Sato Y, et al. Among authors: hirata k. Cancer Chemother Pharmacol. 2010 Sep;66(4):721-8. doi: 10.1007/s00280-009-1215-2. Epub 2009 Dec 30. Cancer Chemother Pharmacol. 2010. PMID: 20041328 Clinical Trial.
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
Sato Y, Ohnuma H, Hirakawa M, Takahashi M, Osuga T, Okagawa Y, Murase K, Takada K, Kawano Y, Iyama S, Hayashi T, Sato T, Miyanishi K, Takimoto R, Kobune M, Okita K, Mizuguchi T, Furuhata T, Hirata K, Kato J. Sato Y, et al. Among authors: hirata k. Cancer Chemother Pharmacol. 2015 Mar;75(3):587-94. doi: 10.1007/s00280-014-2672-9. Epub 2015 Jan 11. Cancer Chemother Pharmacol. 2015. PMID: 25577134 Clinical Trial.
Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy.
Mitsui Y, Sato Y, Miyamoto H, Fujino Y, Takaoka T, Miyoshi J, Kagawa M, Ohnuma H, Hirakawa M, Kubo T, Osuga T, Sagawa T, Sato Y, Takahashi Y, Katsuki S, Okuda T, Takimoto R, Kobune M, Nobuoka T, Hirata K, Kato J, Takayama T. Mitsui Y, et al. Among authors: hirata k. Cancer Chemother Pharmacol. 2015 Aug;76(2):375-82. doi: 10.1007/s00280-015-2807-7. Epub 2015 Jun 23. Cancer Chemother Pharmacol. 2015. PMID: 26099968 Clinical Trial.
A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M, Sato Y, Ohnuma H, Takayama T, Sagawa T, Nobuoka T, Harada K, Miyamoto H, Sato Y, Takahashi Y, Katsuki S, Hirayama M, Takahashi M, Ono M, Maeda M, Takada K, Hayashi T, Sato T, Miyanishi K, Takimoto R, Kobune M, Hirata K, Kato J. Hirakawa M, et al. Among authors: hirata k. Cancer Chemother Pharmacol. 2013 Mar;71(3):789-97. doi: 10.1007/s00280-013-2073-5. Epub 2013 Jan 22. Cancer Chemother Pharmacol. 2013. PMID: 23338051 Clinical Trial.
Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma.
Shima H, Tsurita G, Wada S, Hirohashi Y, Yasui H, Hayashi H, Miyakoshi T, Watanabe K, Murai A, Asanuma H, Tokita S, Kubo T, Nakatsugawa M, Kanaseki T, Tsukahara T, Nakae Y, Sugita O, Ito YM, Ota Y, Kimura Y, Kutomi G, Hirata K, Mizuguchi T, Imai K, Takemasa I, Sato N, Torigoe T. Shima H, et al. Among authors: hirata k. Cancer Sci. 2019 Aug;110(8):2378-2385. doi: 10.1111/cas.14106. Epub 2019 Jul 23. Cancer Sci. 2019. PMID: 31218770 Free PMC article. Clinical Trial.
4,257 results